LUCD Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 11:33):

Stats
Today's Volume	71 930.00
Average Volume	222 227
Market Cap	46.29M
EPS	$-0.250 ( 2024-03-26 )
Next earnings date	( $-0.270 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.740
ATR14	$0.0140 (1.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-08	Matheis Dennis	Buy	241 500	Employee stock option (right to buy)
2024-05-06	Matheis Dennis	Sell	0	Common stock
2024-05-07	Gordon Michael Adam	Buy	400 000	Common stock
2024-05-07	O'neil Shaun	Buy	400 000	Common stock
2024-05-07	Mcgrath Dennis M	Buy	400 000	Common stock

INSIDER POWER
44.28
Last 63 transactions
Buy: 15 024 819 \| Sell: 4 158 892

Volume Correlation

Long: -0.02 (neutral)

Short: 0.67 (moderate)

Signal:(47.469) Neutral

Lucid Diagnostics Inc. Correlation

10 Most Positive Correlations
HCDIP	0.958
NLSP	0.954
HAIN	0.951
SIRI	0.945
NOVN	0.943
TRVN	0.942
PHCF	0.941
RMGC	0.937
TTEC	0.937
FRHC	0.936

10 Most Negative Correlations
TRMR	-0.96
VITL	-0.951
THRN	-0.941
ARTEU	-0.94
GGAL	-0.939
DXPE	-0.937
RZLT	-0.935
CDXC	-0.935
GHRS	-0.934
IXAQ	-0.932

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lucid Diagnostics Inc. Correlation - Currency/Commodity

0.16
( neutral )

0.53
( weak )

0.00
( neutral )

0.66
( moderate )

Lucid Diagnostics Inc. Financials

Annual	2023
Revenue:	$2.43M
Gross Profit:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2023
Revenue:	$2.43M
Gross Profit:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2022
Revenue:	$377 000
Gross Profit:	$-3.24M (-858.62 %)
EPS:	$-1.550

FY	2021
Revenue:	$500 000
Gross Profit:	$-85 000.00 (-17.00 %)
EPS:	$-1.510

Financial Reports:

No articles found.

Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Realtime updates for Lucid Diagnostics Inc. [LUCD]

Upcoming Earnings Alert